ArticleProceedings of the National Academy of Sciences of the United States of America2006
Isolation, characterization, and genetic complementation of a cellular mutant resistant to retroviral infection.
Article in Proceedings of the National Academy of Sciences of the United States of America, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 28 citations in OpenAlex.
- No Time to Fold: Intrinsically Disordered Microproteins in Action.Biochemistry · 2026Review
- Comprehensive analysis of the relationship between RNA modification writers and immune microenvironment in head and neck squamous cell carcinoma.BMC immunology · 2024Article
- Microproteins-Discovery, structure, and function.Proteomics · 2023Review
- Biochemistry and Protein Interactions of the CYREN Microprotein.Biochemistry · 2023Article
- Review
- Ligand binding characteristics of the Ku80 von Willebrand domain.DNA repair · 2020Article
- Modelling of pathogen-host systems using deeper ORF annotations and transcriptomics to inform proteomics analyses.Computational and structural biotechnology journal · 2020Article
- 53BP1: a DSB escort.Genes & development · 2020Review
- Generation of a Mouse Model Lacking the Non-Homologous End-Joining Factor Mri/Cyren.Biomolecules · 2019Article
- MRI Is a DNA Damage Response Adaptor during Classical Non-homologous End Joining.Molecular cell · 2018Article
- Regulation of DNA repair pathway choice in S and G2 phases by the NHEJ inhibitor CYREN.Nature · 2017Article
- The Ku-binding motif is a conserved module for recruitment and stimulation of non-homologous end-joining proteins.Nature communications · 2016Article
- Discovery and characterization of smORF-encoded bioactive polypeptides.Nature chemical biology · 2015Review
- BIRC2/cIAP1 Is a Negative Regulator of HIV-1 Transcription and Can Be Targeted by Smac Mimetics to Promote Reversal of Viral Latency.Cell host & microbe · 2015Article
- Characterization of resistance to rhabdovirus and retrovirus infection in a human myeloid cell line.PloS one · 2015Article
- A human short open reading frame (sORF)-encoded polypeptide that stimulates DNA end joining.The Journal of biological chemistry · 2014Article
- Recurrent mutations in multiple components of the cohesin complex in myeloid neoplasms.Nature genetics · 2013Article
- Isolation and characterization of human cells resistant to retrovirus infection.Retrovirology · 2007Article
- A tractable method for simultaneous modifications to the head and tail of bacteriophage lambda and its application to enhancing phage-mediated gene delivery.Nucleic acids research · 2007Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
Abstract
By using a genetic screen, we have isolated a mammalian cell line that is resistant to infection by retroviruses that are derived from the murine leukemia virus, human immunodeficiency virus type 1, and feline immunodeficiency virus. We demonstrate that the cell line is genetically recessive for the resistance, and hence it is lacking a factor enabling infection by retroviruses. The block to infection is early in the life cycle, at the poorly understood uncoating stage. We implicate the proteasome at uncoating by completely rescuing the resistant phenotype with the proteasomal inhibitor MG-132. We further report on the complementation cloning of a gene (MRI, modulator of retrovirus infection) that can also act to reverse the inhibition of infection in the mutant cell line. These data implicate a role for the proteasome during uncoating, and they suggest that MRI is a regulator of this activity. Finally, we reconcile our findings and other published data to suggest a model for the involvement of the proteasome in the early phase of the retroviral life cycle.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.